ARTICLE | Company News
Santen, R-Tech Ueno deal
June 8, 2015 7:00 AM UTC
Santen granted R-Tech exclusive, worldwide rights to develop and commercialize DE-105. The ophthalmic solution of neurotrophic factor peptide is in Phase II testing in Japan to treat persistent corne...